The tumor microenvironment (TME) plays a crucial role in cancer progression and therapy response. It encompasses a complex network of interactions between malignant and non-transformed cells, including blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix (ECM). Understanding TME and its associated pathways is essential for developing effective therapeutic strategies. Alfa Oncology provides a range of TME pathway-associated products for customers, including antibodies, proteins, and ELISA kits to help them understand TME and related pathways.

Angiogenesis-Related Factors Angiogenesis, the process of forming new blood vessels from the development of existing capillaries or postcapillary veins, is essential for the growth and spread of cancer tumors. It involves the release of certain factors that stimulate the formation of vascular networks that provide nutrients and oxygen to the tumor. Since tumor growth and metastasis are dependent on angiogenesis, inhibition of angiogenesis may hinder tumor progression and restrict its ability to metastasize. Scientists have discovered various angiogenesis inhibitors, and these hold potential as effective treatments for cancer. In addition, the formation and development of blood vessels rely on a delicate balance between factors that promote and inhibit angiogenesis. There are numerous proteins known as angiogenesis activators, such as basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and angiopoietin. These proteins play vital roles in stimulating the process of angiogenesis in various physiological and pathological conditions. Learn more：intracellular signaling factors

Cancer-associated fibroblasts, or CAFs, are a type of stromal cell commonly found in the tumor microenvironment. They are associated with all stages of cancer and contribute to its progression in various ways. CAFs can increase the rate of cancer cell growth, promote the formation of new blood vessels, and facilitate the spread of cancer cells to other parts of the body.

In addition to these effects, CAFs can also suppress the immune system's ability to fight cancer by recruiting immunosuppressive cells and inhibiting the activity of cytotoxic T lymphocytes. This can lead to the development of drug resistance and cancer recurrence. CAFs also play a role in promoting cancer stemness, which can contribute to the resistance of cancer cells to treatment. As such, targeting CAFs has emerged as a promising therapeutic strategy for cancer therapy. Learn more：caf marker antibody